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Th  e occurrence of central neurobiological factors in 
chronic pain states is becoming increasingly observed. 
For ﬁ  bromyalgia (FM), this is certainly true as evidenced 
by the recent article by Fayed and colleagues in the 
previous issue of Arthritis Research and Th  erapy [1]. 
Th  ese authors used a brain imaging tool called proton 
magnetic resonance spectroscopy (1H-MRS), which can 
assess the concentration of speciﬁ  c metabolites in the 
human brain, and looked for altered levels of brain 
neuro  transmitters in individuals with FM. Of particular 
importance to the ﬁ   eld of neurobiology, 1H-MRS 
methods allow for the detection of the brain’s major 
excitatory and inhibitory neurotransmitters, glutamate 
(Glu) and gamma amino-butyric acid (GABA), respec-
tively. To date, this method has been used frequently in 
disorders of the brain, such as depression [2], Alzheimer’s 
disease [3], and epilepsy [4]; recently, however, it is 
becoming increasingly evident that chronic ‘central’ pain 
states such as FM may also have altered brain neuro-
transmitter levels, as evidenced by new 1H-MRS studies 
[5-7].
Fayed and colleagues performed a cross-sectional 1H-
MRS investigation of ten patients with FM and ten sex- 
and age-matched healthy controls, looking at four 
speciﬁ  c brain regions that are thought to be somewhat 
involved in pain processing: the sensorimotor cortex, the 
thalamus, the hippocampus, and the posterior gyrus 
(posterior cingulate). Th  e authors report elevated levels 
of Glx, a combined measure of Glu and glutamine, within 
the posterior cingulate of FM patients. Moreover, they 
observed negative correlations between Glx in the patient 
group and pressure pain thresholds, and positive asso  cia-
tions with these metabolites and scores on the Fibro-
myalgia Impact Questionnaire, suggesting that elevated 
levels of Glx in the posterior cingulate are associated with 
increased pain and tenderness in FM. Th  e posterior 
cingulate region of the brain is also a key component of 
the default mode network (DMN), a constellation of 
brain regions activated during self-referential thinking. In 
FM patients, the DMN appears to have greater functional 
connections with the insula, a key pain processing region, 
and this enhanced connectivity is directly related to the 
spontaneous clinical pain in these patients [8]. In 
aggregate, these data point towards a potential molecular 
basis for some of the functional neuroimaging results 
observed in FM [9,10]: namely, an elevation in brain 
excitatory neurotransmitters that could result in neuronal 
hyperexcitability. Th  is is not the ﬁ  rst such study of 1H-
MRS in FM. Harris and colleagues [5] demonstrated 
elevated levels of Glu and Glx within the posterior insula 
of FM patients, and Valdés and colleagues [6] recently 
reported that Glx was elevated in the amygdala, an 
emotional and pain processing brain region. Th  ese 
ﬁ   ndings, reported by three separate groups, are 
beginning to paint a picture of a more global increase in 
the concentration of the excitatory neurotransmitters in 
the FM brain. It is important to note that across these 
three studies, elevated levels of Glu and Glx were not 
observed in all regions studied. Fayed and colleagues 
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© 2010 BioMed Central Ltdfound elevated Glx in the posterior cingulate but not the 
thalamus or the somatosensory cortex. Valdés and 
colleagues found elevated Glx in the amygdala but not 
the thalamus or prefrontal cortex, and Harris and 
colleagues found elevated Glx in the posterior but not the 
anterior insula. Th   erefore, although multiple brain regions 
may have elevated Glu in FM, this does not appear to be 
the case for every region examined.
As mentioned above, it is tempting to conclude that the 
reason why previous functional magnetic resonance 
imaging studies of FM have observed augmented neural 
activity is due to an elevation of Glu leading to neuronal 
hyperexcitability. At the present moment, however, we 
cannot conclude this for the following reasons: ﬁ  rst, 1H-
MRS-derived levels of Glu are often contaminated in part 
by glutamine [11], thus precluding our ability to assign 
the elevated levels solely to Glu at this time; second, 
within brain tissue, Glu exists in the neurotransmitter 
pool as well as a metabolic pool [12] and we do not know 
if the neurotransmitter pool is where the elevation is 
occurring; and ﬁ   nally, the cellular compartment from 
where the elevated Glu signal is originating is unknown. 
Th  e 1H-MRS signal arises from gray and white matter 
and is an ensemble average of multiple diﬀ  erent  cell 
types, including astrocytes, glia, and neurons. Th  erefore, 
the elevated Glu signal might be at regions distant from 
the synapse.
Unfortunately, answering these questions will require 
novel preclinical research, as they cannot be directly 
assessed with the existing technologies in humans. Th  at 
said, the work by Fayed and colleagues and others contri-
butes signiﬁ   cantly to the ﬁ   eld. It places a key neuro-
transmitter to the forefront of our thinking behind the 
molecular processes involved in FM. It also opens the 
door for 1H-MRS studies of other pain states that may 
also be mediated by central factors. Finally, these data 
also suggest that pharmacologic interventions that 
speciﬁ  cally target glutamatergic neurotransmission may 
be eﬀ  ective in these complex patients. Research in these 
questions is greatly needed.
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